Tests acupoint application with anti-nausea medicine for chemotherapy sickness in lung cancer
Tests acupoint application added to anti-nausea medicine in adults with lung cancer.
Key facts
- Who runs it
- Xiu Huang
- Where
- Chongqing, ChinaSee the site
- Trial code
- Registry title
- Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 15 Jul 2026
- Planned end
- 15 Oct 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 5-HT3 receptor antagonist (e.g., ondansetron)
- Acupoint application
- Record updated
- 17 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lung cancer who are about to start first-line platinum-based chemotherapy. It tests whether acupoint application added to anti-nausea medicine helps control nausea and vomiting.
- Age
- 18 to 75 years
- Sex
- Men and women can join.
- Disease stage
- Lung cancer confirmed by tissue or cell tests. Expected survival of at least 3 months. Karnofsky Performance Status (KPS) score of 60 or more.
- Earlier treatment
- Must be scheduled to receive first-line platinum-based chemotherapy.
Main reasons for not taking part
- Known allergy to any part of the acupoint plaster
- Severe skin disease, infection or broken skin at the planned acupoint sites
- Pregnant or breastfeeding women
- Cognitive or psychiatric problem that prevents completing the study assessments
- Took part in another interventional trial within 30 days before enrollment
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Pathologically or cytologically confirmed lung cancer
- Scheduled to receive first-line platinum-based chemotherapy
- Aged 18 to 75 years
- Karnofsky Performance Status (KPS) score ≥ 60
- Expected survival ≥ 3 months
- Voluntarily signed written informed consent
Who cannot take part
- Participation in another interventional clinical trial within 30 days prior to enrollment
- Known allergy to any component of the acupoint plaster
- Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women
- Cognitive impairment or psychiatric disorder that prevents completion of study assessments
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in China
- The Affiliated Yongchuan Hospital of Chongqing Medical UniversityChongqing, ChinaContact: Xiu HUANGTaking people
About the trial
What the trial wants to find out
This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.
The 2 groups in the trial
- Acupoint application plus 5-HT3 receptor antagonistTreatment being tested
Participants receive herbal acupoint plaster applied to selected acupoints plus standard 5-HT3 receptor antagonist prophylaxis before and during one cycle of platinum-based chemotherapy.
Treatment: 5-HT3 receptor antagonist (e.g., ondansetron) and Acupoint application
- 5-HT3 receptor antagonist aloneExisting treatment, for comparison
Participants receive standard 5-HT3 receptor antagonist prophylaxis alone before and during one cycle of platinum-based chemotherapy.
Treatment: 5-HT3 receptor antagonist (e.g., ondansetron)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial
- Plain-language title
- Tests acupoint application with anti-nausea medicine for chemotherapy sickness in lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07768124, who can take part
- Record updated
- 17 August 2026